Entera Bio’s (ENTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

Entera Bio Price Performance

NASDAQ:ENTX opened at $1.67 on Monday. Entera Bio has a 52-week low of $0.52 and a 52-week high of $3.35. The stock’s 50 day moving average price is $1.86 and its 200 day moving average price is $1.92. The company has a market capitalization of $59.76 million, a PE ratio of -6.42 and a beta of 1.58.

Institutional Investors Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Signature Estate & Investment Advisors LLC bought a new stake in Entera Bio Ltd. (NASDAQ:ENTX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 47,328 shares of the company’s stock, valued at approximately $90,000. Signature Estate & Investment Advisors LLC owned approximately 0.13% of Entera Bio as of its most recent SEC filing. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.